Newly Diagnosed With Leukemia: First Steps

"Leukemia" is not one illness. The four main adult types differ in how fast they move, what confirms them, and how soon treatment starts.

These are the American Cancer Society's projections for the United States in 2026. SEER Stat Facts publishes them and labels them as ACS work.

• Chronic lymphocytic leukemia: about 22,760 new cases and 4,350 deaths.
• Acute myeloid leukemia: about 22,720 new cases and 11,500 deaths.
• Chronic myeloid leukemia: about 9,650 new cases and 1,170 deaths.
• Acute lymphoblastic leukemia: about 6,250 new cases and 1,600 deaths.

The first question to ask is which one you have. Everything else follows from that answer, including whether you are being admitted this week or sent home to be watched.

AML is diagnosed when blasts, meaning immature blood cells, make up 20% or more of cells in blood or marrow. PDQ notes exceptions. Certain chromosome changes settle the diagnosis at lower blast counts. Those include t(15;17), t(8;21), inv(16), and t(16;16).

The median age at diagnosis is 69. PDQ reports that 31.9% of patients were alive 5 years after diagnosis in data from 2014 to 2020. SEER's own stat facts page has since moved to people diagnosed between 2016 and 2022, and puts the figure a little higher, at 33.4%. About 60% to 70% of adults reach complete remission after appropriate induction treatment, and more than 25% may survive 3 years or longer.

PDQ lists factors that worsen the outlook. Older age is one, and disease in the brain or spinal cord is another. A white blood cell count above 100,000 per cubic millimeter counts. So does an active body-wide infection. The last two are leukemia that followed earlier cancer treatment, and a history of myelodysplastic syndrome or another blood disorder before the leukemia.

If you have been told your white count is very high, treat new shortness of breath, confusion, or visual change as an emergency rather than something to mention at the next visit.

Acute promyelocytic leukemia, or APL, makes up 5% to 8% of AML. PDQ calls it a medical emergency. The reason is its strong link to disseminated intravascular coagulation, a bleeding and clotting disorder.

It is also the AML subtype with the best outcomes, because it responds to a specific drug. All-trans retinoic acid, or ATRA, is a differentiating agent. It pushes the abnormal cells to mature. PDQ describes ATRA combined with chemotherapy. It also describes chemotherapy-free regimens built on arsenic trioxide. Both reach high complete remission rates.

This is why the cytogenetic result is urgent, not routine. Ask specifically whether APL has been ruled in or out, and how soon that result is expected.

Go to an emergency department for new bleeding from the gums or nose, unusual bruising, or blood in urine or stool while this is being sorted out.

Adult ALL treatment runs in three phases and takes 1.5 to 3 years in total.

Remission induction combines several drugs. The core is vincristine, prednisone, and an anthracycline, with or without asparaginase. PDQ reports complete remission in 60% to 80%.

Central nervous system prophylaxis is a separate phase and is not optional. Leukemia cells can hide in the fluid around the brain and spinal cord. Standard chemotherapy given by vein reaches that space poorly. PDQ names three tools. They are methotrexate injected into the spinal fluid, high-dose methotrexate by vein, and radiation to the head.

Consolidation follows, using intensive chemotherapy or an allogeneic bone marrow transplant in eligible patients.

One genetic result reshapes the plan. The Philadelphia chromosome appears in roughly 20% of adults with ALL. PDQ notes it may be detectable only by FISH or RT-PCR, so it can be missed on routine chromosome analysis. Adding a BCR::ABL1 tyrosine kinase inhibitor to chemotherapy improved outcomes for this group. PDQ reports a 5-year overall survival of 39%.

CML is defined by a single genetic event. PDQ states that over 95% of patients carry the Philadelphia chromosome. It forms when chromosomes 9 and 22 swap material. The result is the BCR::ABL1 fusion gene. It makes an abnormal tyrosine kinase that drives the disease.

Phase is set by blast percentage. Chronic phase is under 10%. Accelerated phase is 10% to 19%. Blastic phase is 20% or more. Most patients present in chronic phase.

PDQ lists five tyrosine kinase inhibitors used first line: asciminib, nilotinib, dasatinib, bosutinib, and imatinib. With any of them, 10-year event-free and overall survival exceed 90%, and PDQ states median survival is projected to approach normal life expectancy.

Monitoring uses the BCR::ABL1 transcript level, measured by RT-PCR:

• Early molecular response: 10% or less at 3 months.
• Major molecular response: 0.1% or less.
• Deep molecular response: 0.01% or less.

PDQ notes that reaching 10% or less at 3 months predicts better long-term outcomes.

Stopping is sometimes discussed, but PDQ is cautious. It says it is unclear whether TKI therapy can be discontinued. The best candidates are people who have taken a TKI for more than 3 to 5 years and reached a deep response of 0.0032% or less. Even then, about 50% relapse after stopping, though one retrospective analysis of people in deep response for 5 years or more put the relapse rate near 10%. Almost all who relapse on PCR testing can be restarted successfully. This is a conversation to have with your hematologist, not a step to take alone.

CLL needs two things. One is a blood lymphocyte count of 5,000 per cubic millimeter or higher. The other is a telltale flow cytometry pattern: B cells carrying CD19 and CD20 alongside CD5, a T-cell marker, plus CD23. PDQ notes only one other disease shows that combination, mantle cell lymphoma.

Then, often, nothing happens. Observation is standard for people without symptoms. PDQ cites a meta-analysis of randomized trials. It found no survival gain from early treatment over delayed treatment in early-stage disease. Treatment begins for progressive marrow failure or symptomatic disease.

That waiting is a plan, not neglect. It helps to have the prognostic numbers, which PDQ gives:

• Unmutated IGHV: median survival 8 to 10 years. Mutated IGHV: 20 to 25 years.
• del(17p) or a TP53 variant: worst group, median overall survival about 7 years.
• del(13q): favorable, median overall survival about 17 years.

Frontline options PDQ names include ibrutinib, acalabrutinib, and venetoclax. Chemotherapy with fludarabine, cyclophosphamide, and rituximab is still an option. It suits younger patients with mutated IGHV best.

Rai staging runs from stage 0, lymphocytosis alone, to stage IV, lymphocytosis with low platelets. The Binet system sorts patients into A, B, or C.

Across types, the workup is similar in shape.

• Complete blood count with differential.
• Chemistry panel. It covers uric acid, creatinine, potassium, phosphate, calcium, bilirubin, and liver enzymes.
• Coagulation studies and screening for infection.
• Bone marrow aspirate and biopsy.
• Flow cytometry, which identifies the cell type by its surface markers.
• Cytogenetic analysis. PDQ calls it mandatory in suspected AML. About 50% of those cases carry a chromosome abnormality.
• Molecular testing. In AML, PDQ names NPM1, FLT3, CEBPA, and RUNX1. In ALL and CML, RT-PCR and FISH for BCR::ABL1.

In AML, PDQ ranks cytogenetic and molecular results as the strongest guide to outlook. They predict how induction and consolidation therapy will go.

• Exactly which leukemia is this, and what confirmed it?
• What was my blast percentage, and in blood or in marrow?
• Have cytogenetics and molecular testing been sent, and when do results return?
• For AML, has APL been ruled out?
• Does my plan start now, or is observation appropriate?
• What is my white blood cell count, and does it need lowering urgently?
• Which symptoms should send me to the emergency department rather than the clinic?

• https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq
• https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq
• https://www.cancer.gov/types/leukemia/hp/cml-treatment-pdq
• https://www.cancer.gov/types/leukemia/hp/cll-treatment-pdq